Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2022 | Recent developments in treating TNBC with targeted therapies

Philippe Georges Aftimos • 5 Jun 2022
ASCO 2022
Breast Cancer Antibodies Sacituzumab govitecan

The advent of anti-PD-L1 immunotherapies have significantly improved the treatment landscape of triple-negative breast cancer (TNBC). Philippe Georges Aftimos, MD, Institut Jules Bordet, Brussels, Belgium, provides an overview of current advances in the uses of targeted therapies for TNBC, including the recent approval of sacituzumab govitecan, an antibody–drug conjugate (ADC). Dr Aftimos additionally highlights novel PARP inhibitors, targeting BRCA1/2, as well as novel targets such as NOTCH. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.

More from Philippe Georges Aftimos

Breast cancer highlights at ASCO 2022
0:54
Breast cancer highlights at ASCO 2022
Philippe Georges Aftimos • 5 Jun 2022
ZEN-3694, a novel BET inhibitor, in TNBC without germline BRCA1/2 mutations
3:39
ZEN-3694, a novel BET inhibitor, in TNBC without germline BRCA1/2 mutations
Philippe Georges Aftimos • 5 Jun 2022

Related Videos

How will SARMs fit into the current breast cancer treatment paradigm?
1:14
How will SARMs fit into the current breast cancer treatment paradigm?
Rafael Grochot • 2 Jul 2026
Phase I/II trial of vosilasarm and endocrine therapy in AR+/ER+/HER2− breast cancer
1:35
Phase I/II trial of vosilasarm and endocrine therapy in AR+/ER+/HER2− breast cancer
Rafael Grochot • 2 Jul 2026
HYPORT: does the number of fractions of RNRT impact the typical symptoms experienced?
1:07
HYPORT: does the number of fractions of RNRT impact the typical symptoms experienced?
Sanjoy Chatterjee • 17 May 2026
Design and aim of the HYPORT study in regional nodal breast cancer
1:23
Design and aim of the HYPORT study in regional nodal breast cancer
Sanjoy Chatterjee • 17 May 2026

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJOncology is intended for healthcare professionals